Navigation Links
Pharmacyclics Reports Second Quarter Fiscal 2009 Financial Results
Date:2/13/2009

SUNNYVALE, Calif., Feb. 13 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) today reported financial results for its second fiscal quarter ended December 31, 2008. The net loss for the second quarter of fiscal 2009 was $4.8 million, or $0.19 per share, compared to a net loss of $5.9 million, or $0.23 per share, in the second quarter of fiscal 2008.

Total operating expenses were $4.9 million in the second quarter of fiscal 2009, including $0.4 million of severance related share-based compensation expense and $0.2 million of cash severance expense. Excluding the $0.6 million of severance related expenses, total expenses were $4.3 million in the second quarter of fiscal 2009 compared to $6.2 million for the second quarter of fiscal 2008, a decrease of $1.9 million. Excluding $0.4 million in severance related share-based compensation expense, share-based compensation expense was $0.2 million in the second quarter of fiscal 2009 compared to $0.6 million in the second quarter of fiscal 2008. The decrease of $1.9 million in total operating expenses, after excluding the severance related expenses, in the second quarter of fiscal 2009 was primarily due to reduced personnel expenses due to lower headcount and reduced manufacturing costs and outside preclinical expenses associated with the company's HDAC, Btk and Factor VIIa inhibitor programs.

Pharmacyclics also reported its financial results for the six months ended December 31, 2008. The net loss for the six months ended December 31, 2008 was $11.4 million, or $0.44 per share, compared to a net loss of $12.7 million, or $0.49 per share, for the six months ended December 31, 2007. The net loss for the six months ended December 31, 2008 included $2.5 million of severance related expenses.

As of December 31, 2008, the Company's cash, cash equ
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
2. Pharmacyclics Secures $5.0 Million in Debt Financing
3. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
4. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
5. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
6. Pharmacyclics Announces It Received Nasdaq Notification
7. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
8. YM BIOSCIENCES REPORTS SECOND QUARTER 2009 OPERATIONAL AND FINANCIAL RESULTS
9. Shengtai Pharmaceutical, Inc. Reports Second Quarter Fiscal 2009 Financial Results
10. Neurobiological Technologies Reports Second Quarter Fiscal 2009 Financial Results
11. Corgenix Reports Second Quarter Fiscal 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Research and Markets ... of the "Oxidative Stress Assay Market ... (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), Technology ... Global Forecast to 2020" report to ... , The global oxidative stress ...
(Date:6/1/2015)... and RARITAN, N.J. , ... LLC (Janssen) announced data from the Phase 3 ... in progression-free survival (PFS) with trabectedin (YONDELIS ® ... liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with ... regimen. SAR3007 is the largest randomized Phase 3 ...
(Date:6/1/2015)... NEW YORK , June 1, 2015 ... produced by the fermentation of sugar or cellulose. Bio-alcohols ... bio-ethanol can be used as a replacement for gasoline ... to grow at a CAGR of 9 percent over ... Report The global bio-alcohols market can be segmented into ...
(Date:6/1/2015)... EAST HANOVER, N.J. , June 1, 2015 ... Phase II clinical study of CTL019, an investigational ... indicate its potential in the treatment of specific ... ongoing study conducted by the University of Pennsylvania,s ... relapsed or refractory (r/r) diffuse large B-cell lymphoma ...
Breaking Biology Technology:Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 2Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 3Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 4Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 5Novartis highlights CTL019 data showing its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma 6
... Life Sciences Holdings, Inc. (OTC Bulletin Board: ... discovery, development and commercialization of novel drugs in the ... announced that it will present at the Biotech Showcase ... Francisco. (Logo: http://photos.prnewswire.com/prnh/20080218/ALSLOGO ) ...
... Jan. 4, 2011 Vaccinex, Inc. announced today that ... a Phase 1 clinical trial to assess the safety, ... in cancer patients with advanced solid tumors. ... novel humanized antibody that blocks the activity of semaphorin ...
... S.C., Jan. 4, 2011 Zeus, Inc., a global ... it has expanded its capabilities and is now able ... new 5,000-sq-ft Class 7 manufacturing environment. This expansion allows ... more controlled environment, resulting in compliance with stricter regulatory ...
Cached Biology Technology:Advanced Life Sciences to Present at the Biotech Showcase™ 2011 Conference 2Vaccinex, Inc. Initiates Clinical Trial of Novel Therapeutic Antibody in Cancer Patients With Advanced Solid Tumors 2Zeus Expands Class 7 Capabilities to Include the Processing of Advanced Polymers 2
(Date:5/19/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
(Date:5/14/2015)... YORK , May 14, 2015 /PRNewswire/ ... in identity verification and online remote proctoring, ... a software-as-a-service (SaaS) company and creator of ... customers of the two companies will benefit ... in Canvas. As a fully ...
(Date:5/8/2015)... 8, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... members of the executive management team will present at the ... Media and Telecom Conference Date: May 18, 2015 ... Boston, MA Cowen and Company Technology, ... ET Location: The New York Palace Hotel, New ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... of fossil speculation across the American West escalated into a ... the spectacle were two scientists from the Lone Star State: ... Texas Geology, and naturalist Jacob Boll, who made many of ... supporting roles in the Bone Wars through their work for ...
... University have found that, over a period of five months ... naturally-occurring bacteria that exist in the Gulf of Mexico consumed ... gas that spewed into the deep Gulf from the ruptured ... to determine not only how much oil and gas was ...
... to change their behavior if they voluntarily commit to ... to a new study in the Journal of ... you,re trying to encourage more eco-friendly behavior. "Commitment ... specific steps to promote the desired behavior. Consumers who ...
Cached Biology News:Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 2Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 3Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 4Newly discovered letters and translated German ode expand Texas link to infamous Bone Wars 5At least 200,000 tons of oil and gas from Deepwater Horizon spill consumed by gulf bacteria 2At least 200,000 tons of oil and gas from Deepwater Horizon spill consumed by gulf bacteria 3Want to encourage eco-friendly behavior? Give consumers a nudge (Don't tell them what to do) 2
... FAST RED Chromogen System consists ... substrate buffer. FAST RED reacts ... phosphatase to produce red staining ... The FAST RED ...
Mouse Cell Line Slides...
Human Cell Line Slides...
... most comprehensive, cost-effective solution to your ... unprecedented quality into both our products ... detection chemistries and antibodies that have ... It also includes our competitively priced ...
Biology Products: